PM1183 plus doxorubicin shows interesting activity in small cell lung cancer
2 Visninger
• 07/14/23
0
0
Indlejre
administrator
Abonnenter
Visit http://www.ecancer.org for more
Dr Calvo (START Madrid, Madrid, Spain) talks to ecancertv at ASCO 2015 about data from a Phase 1b study of the transcriptional inhibitor PM1183 in combination with doxorubicin in second line therapy in patients with small cell lung cancer (SCLC)
Vis mere
Facebook kommentarer
SORT BY-
Topkommentarer
-
Seneste kommentarer